Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|February 1, 2015
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes MellitusSilke Retlich, Vincent Duval, Ulrike Graefe-Mody, et al.
British Journal of Clinical Pharmacology|February 28, 2007
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's diseaseThorsten Lehr, Alexander Staab, Christiane Tillmann, et al.
Journal of Clinical Pharmacology|September 30, 2011
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationThorsten Lehr, Sebastian Haertter, Karl-Heinz Liesenfeld, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|January 8, 2014
Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitusYusuke Tadayasu, Akiko Sarashina, Yasuhiro Tsuda, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 10, 2018
Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future PerspectivesScott Marshall, Rajanikanth Madabushi, Efthymios Manolis, et al.
Pharmaceutical Research|September 14, 2004
Population dose-response model for tadalafil in the treatment of male erectile dysfunctionAlexander Staab, Christiane Tillmann, S Thomas Forgue, et al.
Journal of Clinical Pharmacology|August 14, 2013
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesMatthew M Riggs, Alexander Staab, Leo Seman, et al.
Pharmacogenetics and Genomics|August 24, 2011
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapineThorsten Lehr, Jing Yuan, David Hall, et al.
Clinical Pharmacokinetics|November 9, 2010
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjectsSilke Retlich, Vincent Duval, Arne Ring, et al.
International Journal of Oncology|March 3, 2007
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neckAlexander Sauter, Charlotte Kloft, Silke Gronau, et al.
Pageof 4